Clinical Evaluation of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease

Sponsor
BlueDop Medical LTD (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05073510
Collaborator
AKRN Scientific Consulting, S.L. (Industry)
158
4
6.6
39.5
6

Study Details

Study Description

Brief Summary

This is a BlueDop Vascular Expert System (BVE) Post-Market Clinical Follow-Up (PMCF) study. The primary objective of the study is to assess the clinical applicability and diagnostic accuracy of the BVE device in subjects who require an arterial duplex test due to suspected peripheral arterial disease (PAD).

Condition or Disease Intervention/Treatment Phase
  • Device: BVE

Detailed Description

The BVE device is intended to assess mean peripheral pressure, vascular reserve, Cuff free Ankle Brachial Index (ABIm), and assess the presence or absence of hemodynamically significant arterial disease. By converting Doppler shifts to a blood pressure measurement, BVE can be used to monitor PAD in a non-invasive manner without confounding by arterial calcification.

This is a post-market, interventional, prospective, multi-center, open-label, non-randomized, single-arm clinical investigation designed to evaluate the clinical equivalence of BVE to arterial Duplex in a group of patients referred for evaluation of PAD of the limbs when performed by a vascular specialist. Moreover, the evaluation of the clinical performance including inter-operator variability and BVE non-diagnostic rate will be also carried out as exploratory variables.

  1. Primary objective:

Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to arterial duplex ultrasound in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.

  1. Secondary objectives:

Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to ankle brachial pressure index (ABPI) in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.

Assess the safety of the BVE device.

  1. Exploratory objectives:

Evaluation of the BVE System for clinical performance including time needed to perform BVE, inter-operator variability and number of BVE non-diagnostic tests.

Study Design

Study Type:
Observational
Anticipated Enrollment :
158 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective, Multicenter, Nonrandomized, Open-label, Single-arm Study of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease
Actual Study Start Date :
Oct 11, 2021
Anticipated Primary Completion Date :
Apr 30, 2022
Anticipated Study Completion Date :
Apr 30, 2022

Arms and Interventions

Arm Intervention/Treatment
BlueDop Vascular Expert (BVE)

PAD assessment with BVE

Device: BVE
Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)

Outcome Measures

Primary Outcome Measures

  1. Determination of presence or absence of significant PAD with BVE and Arterial duplex [1 day]

    Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of the arterial duplex. Significant PAD is established with Duplex ultrasound when peak systolic velocity ratio (PSVR) is greater than 3 for any one level, or, if patients have multi-level disease, PSVR ≥ 2 at more than one level (i.e. sfa, pop)

Secondary Outcome Measures

  1. Determination of presence or absence of significant PAD with BVE and ABPI [1 day]

    Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of ABPI. Significant PAD is established when ABPI index is <0.8.

  2. Number and risk-classification of Adverse Events (AEs) and Serious Adverse Events (SAEs) [1 day]

    Evaluation of BVE safety through the assessment of the risk and occurrence rates of AEs and SAEs

Other Outcome Measures

  1. Time spent for arterial duplex, BVE and ABPI vascular assessment [1 day]

    Comparison of the time to perform a vascular assessment using arterial duplex, BVE, and ABPI (when available).

  2. Determination of presence or absence of significant PAD with BVE by vascular and non-vascular experts [1 day]

    Evaluation of clinical equivalence of BVE testing performed by staff specifically trained on BVE who are not vascular technologists/specialists compared to BVE testing performed by vascular technologists/specialists.

  3. BVE non-diagnostic rate [1 day]

    Number of patients and/or limbs that could not be assessed by BVE.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Subject must provide written informed consent prior to any clinical investigation related procedure.

  2. At least 18 years of age.

  3. Referred for duplex ultrasound of the lower limb (s) with suspected or previous history of peripheral arterial disease

  4. Must have an ABPI performed as part of the assessment

  5. Able to obtain a brachial cuff blood pressure reading

  6. Must have a valid ankle duplex ultrasound measurement at the Posterior Tibial Artery (PTA) and Dorsalis Pedis Artey (DPA)

Exclusion Criteria:
  1. Subject is currently participating in another clinical investigation or has participated in another clinical investigation in the past 30 days prior to the start of the present study;

  2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period

  3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness;

  4. Inability or refusal to give informed consent

  5. Lower extremity wound or compromised skin of the legs that prevents access to the studied arteries

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Los Madroños Brunete Madrid Spain 28690
2 Hospital de Manises Manises Valencia Spain 46940
3 Clínica Universidad de Navarra Madrid Spain 28027
4 Hospital Doctor Peset Valencia Spain 46017

Sponsors and Collaborators

  • BlueDop Medical LTD
  • AKRN Scientific Consulting, S.L.

Investigators

  • Principal Investigator: José Ignacio Leal Lorenzo, Clínica Universidad de Navarra

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
BlueDop Medical LTD
ClinicalTrials.gov Identifier:
NCT05073510
Other Study ID Numbers:
  • BVE-01
First Posted:
Oct 11, 2021
Last Update Posted:
Oct 22, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by BlueDop Medical LTD
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 22, 2021